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Cancer Metabolism
Hypoxia and hyperglycaemia determine why some
endometrial tumours fail to respond to metformin
Vanitha N. Sivalingam1,2, Ayşe Latif3, Sarah Kitson1,2, Rhona McVey4, Katherine G. Finegan3, Kay Marshall3, Michael P. Lisanti5,
Federica Sotgia5, Ian J. Stratford3 and Emma J. Crosbie 1,2
BACKGROUND: High expression of Ki67, a proliferation marker, is associated with reduced endometrial cancer-speciﬁc survival.
Pre-surgical metformin reduces tumour Ki-67 expression in some women with endometrial cancer. Metformin’s anti-cancer activity
may relate to effects on cellular energy metabolism. Since tumour hypoxia and glucose availability are major cellular redox
determinants, we evaluated their role in endometrial cancer response to metformin.
METHODS: Endometrial cancer biopsies from women treated with pre-surgical metformin were tested for the hypoxia markers,
HIF-1α and CA-9. Endometrial cancer cell lines were treated with metformin in variable glucose concentrations in normoxia or
hypoxia and cell viability, mitochondrial biogenesis, function and energy metabolism were assessed.
RESULTS: In women treated with metformin (n= 28), Ki-67 response was lower in hypoxic tumours. Metformin showed minimal
cytostatic effects towards Ishikawa and HEC1A cells in conventional medium (25mM glucose). In low glucose (5.5 mM), a dose-
dependent cytostatic effect was observed in normoxia but attenuated in hypoxia. Tumours treated with metformin showed
increased mitochondrial mass (n= 25), while in cultured cells metformin decreased mitochondrial function. Metformin targets
mitochondrial respiration, however, in hypoxic, high glucose conditions, there was a switch to glycolytic metabolism and decreased
metformin response.
CONCLUSIONS: Understanding the metabolic adaptations of endometrial tumours may identify patients likely to derive clinical
beneﬁt from metformin.
British Journal of Cancer https://doi.org/10.1038/s41416-019-0627-y
BACKGROUND
Endometrial cancer is the most common gynaecological malig-
nancy in developed countries. In the United Kingdom, the
incidence has almost doubled since the 1990s,1 driven mainly
by the obesity epidemic.2 Similar trends have been reported in the
United States, with an estimated 60,500 new cases in 2016.3
Insulin resistance often co-exists with obesity and is an
independent risk factor for endometrial cancer. Surgical treatment
of early stage endometrial cancer is usually curative, but is
accompanied by increased peri-operative morbidity in obese
women.4 Current non-surgical alternatives offer lower rates of cure
and are associated with a high risk of relapse.5,6 Thus, there is a
need to explore new, efﬁcacious, non-surgical approaches for
those unsuitable for surgery, those who wish to avoid a
hysterectomy for fertility reasons, as well as for women with
advanced, recurrent endometrial cancer.
Metformin, long used in the treatment of type 2 diabetes, has
shown promise as an anti-cancer drug in endometrial cancer.7 We
found that short-term pre-surgical treatment with metformin
reduced tumour proliferation in some non-diabetic women with
endometrioid endometrial cancer. The response was measured by
change in Ki-67, a cellular proliferation marker, and individual
women varied in their response.8 In exploratory subgroup
analyses, associations with body mass index were observed;
leaner women showed a greater Ki-67 change post-treatment
than obese women.8,9 Heterogeneity of response to metformin
has been documented in other pre-surgical window studies in
endometrial,9–12 breast13–15 and prostate cancer16 and is likely to
be related to both patient- and tumour-associated factors.
In type 2 diabetes, metformin increases insulin sensitivity and
reduces serum glucose concentration through enhanced
myocyte-driven glucose uptake and inhibition of hepatic gluco-
neogenesis.17 At a cellular level, metformin is a mitochondrial
toxin that affects energy balance through inhibition of mitochon-
drial electron transport, leading to a reduction in oxidative
phosphorylation.18 Higher doses of metformin or combination
therapy are required for obese patients with severe type 2
diabetes and extreme hyperglycaemia.19 A hallmark of cancer is
metabolic reprogramming with an increased consumption of
glucose and glutamine.20 Cancer cells, however, can alter their
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metabolism to adapt to decreased oxygen availability in the
microenvironment with the activation of certain genes including
hypoxia-inducible factor-1α (HIF-1α) and its downstream target,
carbonic anhydrase 9 (CA-9).21 Thus, hyperglycaemia and local
hypoxia may drive resistance to metformin. One such resistance
mechanism is a preferential switch from oxidative phosphoryla-
tion to glycolytic metabolism.22 We, therefore, hypothesised that
the anti-cancer activity of metformin could vary according to
tissue glucose and oxygen availability. The objective of our work
was to establish metabolic determinants of metformin response,
with the ultimate aim of identifying endometrial cancer patients
most likely to derive clinical beneﬁt from metformin.
METHODS
Cell lines, cell culture and treatments
Ishikawa (99040201, HPA Culture Collections, Salisbury, UK) and
HEC1A (HTB-112, ATCC, Middlesex, UK) cells were maintained in
DMEM growth medium (LTC, Paisley, UK) supplemented with 10%
heat-inactivated FBS and Glutamax. Ishikawa and HEC1A cells
were originally established from well differentiated23 and moder-
ately differentiated24 endometrioid endometrial adenocarcino-
mas, respectively. Cells used in experiments were at passage 5–8
(post purchase of frozen stocks). For cells used beyond this early
passage, they were authenticated during and at the end of the
study using the DNA sequencing facility the Cultures Collection,
Public Health England. Cells were tested every 3–4 weeks for
mycoplasma and shown to be negative throughout the study. For
in vitro studies, metformin (1,1-dimethylbiguanide hydrochloride)
(Sigma-Aldrich, Dorset, UK) was diluted in a PBS stock solution and
used at concentrations detailed.
Cytostatic assays
For cytostatic assays, Ishikawa and HEC1A cells were plated in 96-
well plates at concentrations of 5000 and 10,000 cells/well,
respectively. Cells were treated in DMEM with low (5.5 mM) or
high (25 mM) glucose, subsequently referred to as low and high
glucose. These two concentrations of glucose were chosen
because standard growth media contains 25 mM glucose and
most previous studies of the action of metformin in vitro have
been carried out in media containing this glucose concentra-
tion.25–28 However, 25 mM glucose in vitro is comparable with
extreme hyperglycaemia in humans, while 5.5 mM glucose in vitro
is more consistent with normoglycaemic serum concentrations.
For hypoxic conditions, cells were incubated in hypoxia (1% O2)
for 24 h and then treated for a further 24–72 h in hypoxia with
metformin-supplemented media or vehicle alone. After treatment,
cells were ﬁxed with 10% (w/v) trichloroacetic acid and incubated
with sulforhodamine B (SRB) for 15 min, followed by 1% (v/v)
acetic acid washing and drying steps. Finally, the protein-bound
dye was dissolved in 10 mM Tris at pH 8.8 and optical density read
at 540 nm.29 The optical density is directly proportional to cell
number and results are presented as a percentage of cells in
treated groups compared with untreated controls.
Mitochondrial ﬂow cytometric assay
Fluorescent-activated cell sorting (FACS) was used to assess
mitochondrial mass and function in Ishikawa and HEC1A cells
plated in 6 well plates at 20,000 and 30,000 cells/well, respectively.
Cells were cultured in low and high glucose media for 24 h, then
treated with 2 mM metformin (chosen as it showed less than 50%
cytostatic behaviour in both cell lines in high and low glucose) or
vehicle alone for 72 h.
MitoTracker Deep Red (M22426) (Molecular Probes, UK) and
Mitotracker Orange CMTMRos (M7510) (Molecular Probes, UK)
were used to measure mitochondrial mass and function in live
cells. A change in the mitochondrial membrane potential, as
assessed by MitoTracker Orange CMTMRos was used as a measure
of change in mitochondrial function. Cells were incubated in
MitoTracker staining solution [50 nM MitoTracker in PBS (phos-
phate-buffered saline0 with added MgCl2/CaCl2], prior to washing
with PBS, harvesting and sorting for ﬂow cytometric analysis
(Fortessa, BD Bioscience, UK). Flowjo software was used to identify
dead cells, couplets and debris, ensuring that cells analysed were
single cells.
Extracellular ﬂux analysis
Cellular mitochondrial function was additionally measured using a
Seahorse XFe96 Analyser and a XF Cell Mito Stress Test (Agilent
Technologies, Santa Clara, USA). Ishikawa and HEC1A cells were
incubated in low and high glucose media, supplemented with L-
glutamine. Cells in 96 well plates were treated for 24 h with 2 mM
metformin or vehicle alone in low and high glucose media,
concurrently in normoxia or hypoxia (3% O2). An oxygen tension
of 3% is the lowest at which the extracellular ﬂux analysis provides
reproducible measurements of oxygen consumption. Cell num-
bers were optimised to provide reproducible changes in oxygen
consumption rate (OCR) and restoration to the ambient oxygen
concentrations between measurements (normoxia or 3% O2;
Supplementary Figs. 1 and 2). For hypoxia assays, all manipula-
tions including the Seahorse analyses were carried out under
hypoxic conditions using the Whitley H35 Hypoxystation and
Whitley i2 Instrument Workstation (Don Whitley Scientiﬁc, Bingley,
UK). A mixing step was used to restore oxygen levels between
each measurement cycle to ensure reliable repeated measure-
ments of OCR in normoxia and hypoxia (3% O2). Maintenance of
hypoxia was conﬁrmed using a NaSO3 control. (Supplementary
Fig. 2).
During the XF Cell Mito Stress Test, OCR (pMoles O2 consumed/
minute) and ECAR (extracellular acidiﬁcation rate, measured as
change in mpH units/min) could be measured simultaneously.
After replacement of growth media with Seahorse buffer contain-
ing metformin or vehicle, the mitochondrial function was assayed
by sequential injections of oligomycin (ATP synthase inhibitor),
FCCP (carbonylcyanide p-triﬂuoromethoxy phenylhydrazone),
mitochondrial oxidative phosphorylation protonophore and
uncoupler, rotenone (mitochondrial complex I inhibitor) and
antimycin A (mitochondrial complex III inhibitor) (Agilent Tech-
nologies, Santa Clara, US). This allowed us to deﬁne basal OCR,
ATP-linked OCR, proton leak, maximal respiratory capacity, reserve
respiratory capacity and non-mitochondrial oxygen consumption.
To normalise the results, cell number/well was quantiﬁed using
the SRB assay at the end of the recording.
After normalising to cell numbers, ECAR and OCR values were
and plotted as mean ± SEM. A schematic representation is given in
Supplementary Fig. 1. Basal ECAR (basal glycolytic and non-
glycolytic acidiﬁcation) was measured during the assessment of
basal respiration in cells already conditioned in glucose to
determine the effect of metformin pre-treatment on glycolysis.
ECAR measured following oligomycin, which effectively shuts
down oxidative phosphorylation represents maximum glycolytic
capacity, ECAR measured after rotenone and antimycin A
injections represent non-glycolytic acidiﬁcation. This allows
calculation of glycolytic reserve; i.e. the capacity of a cell to
respond to energetic demand (Supplementary Fig. 1).
Glycolytic reserve=maximum ECAR (glycolytic capacity+ non-
glycolytic acidiﬁcation)− basal ECAR (glycolysis+ on glycolytic
acidiﬁcation)
RNA extraction and real-time PCR
The expression of hypoxia-dependent genes (VEGF, GLUT-1 and
CA-9) was quantiﬁed using qRT-PCR to conﬁrm hypoxia induction
at 3% O2 levels. Total RNA was extracted from ﬁxed cells following
extracellular ﬂux analysis according to the PrimeScript TMRT
reagent kit (Ambion RNA, Thermo-Fisher Scientiﬁc, UK). Extracted
RNA was subjected to a DNA-free reaction and converted to cDNA
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via reverse-transcription. Subsequent cDNA was analysed by real-
time PCR using the Applied Biosystems 7000 Sequence Detection
System. Detailed methodology is available in the supplementary
information. All real-time experiments were carried out in
duplicate and at the end of the PCR the calculated cycle threshold
(CT) values were analysed. Relative mRNA levels of vascular
endothelial growth factor (VEGF), Carbonic Anhydrase-9 (CA-9)
and Glucose Transporter-1 (GLUT-1) from the two different cell
lines were normalised to levels of hypoxanthine-guanine phos-
phoribosyltransferase (HPRT), which does not change following
hypoxic exposure.
Pre-surgical window study
Approval was received from the North West Centre for Research
Ethics Committee and all participants provided informed consent.
Women with atypical endometrial hyperplasia or endometrioid
endometrial adenocarcinoma received metformin 850mg twice
daily (n= 28) or no drug (n= 12) in the pre-surgical window
(median 20 days) between diagnosis and hysterectomy. Endome-
trial cancer tissue proliferation markers, serum markers of insulin
resistance and anthropometrics were measured before and after
the pre-surgical window as previously described.8
Immunohistochemistry
Hypoxia-inducible factor-1α (HIF-1α) and CA-9 expression were
assessed on tissue microarrays (TMAs) (n= 40). TMAs were created
from triplicate cores taken from equivalent areas in the pre- and
post-intervention biopsies by the study histopathologist who was
blinded to treatment arm, as previously described.8 Selection was
not based on vascular “hot spots”, and instead provided tumour
representative of equivalent grade in the paired samples. Areas of
tumour necrosis were avoided. Immunohistochemistry was
performed on parafﬁn-embedded tissue sections using the Leica
Bond Max (Leica Biosystems, Wetzlar, Germany). Ki-67 staining and
scoring has been described previously.30 Sections were de-
parafﬁnised, rehydrated and underwent heat-induced epitope
retrieval unless stated. Full details of the antibodies and conditions
are given in Supplementary Table 1. Primary antibodies used were
HIF-1α (BD 610959, BD Biosciences, UK) and CA-9 (NB100-147,
Novus Biological, Colorado, US). Translocase of the outer
mitochondrial membrane 20 (TOMM20) (#sc-17764, Santa Cruz
Biotech, Dallas, US) staining was performed on whole sections in
women where sufﬁcient pre- and post-intervention tissue was
available (n= 33/40). TOMM20 expression has been shown to
correlate with mitochondrial mass and function.31 The primary
antibody detection was performed using a post-primary solution
and polymer detection which utilised a rabbit anti-mouse IgG
secondary and anti-rabbit poly HRP IgG antibodies. This was
followed by 3,3’-diaminobenzidine (DAB) staining as a chromogen
(Reﬁne Detection Kit, Leica Biosystems, Wetzlar, Germany).
Slides (TMAs and whole sections) were digitised (Leica SCN400
Slide Scanner, Wetzlar, Germany) and all malignant glands within
the triplicate cores were scored. HIF-1α (nuclear) CA-9 (cytoplas-
mic and membrane) and TOMM20 (cytoplasmic) staining were
assessed using a modiﬁed H-score, calculated as the product of
the area of positive staining (scored 0–6) and the intensity of
staining (scored 0= none, 1=mild, 2=moderate, 3= strong),
giving a maximum of 18. All scoring was performed by
independently by two separate individuals who were blinded to
the treatment group. The inter-observer intra-class correlation
coefﬁcient was 0.98 (95% CI 0.95-0.99), 0.92 (95% CI 0.77-0.96) and
0.91 (95% CI 0.67-0.96) for HIF-1α, CA-9 and TOMM20, respectively.
Any discrepancies of greater than 10% were reviewed collectively
and resolved by consensus agreement.
Statistical analysis
All statistical analyses were performed using GraphPad Prism
version 6.0 and IBM SPSS Statistics version 23.0. Cell culture
experiments were carried out in triplicate on three independent
occasions (unless otherwise stated). Data are presented as mean ±
SEM. Parametric data were analysed using unpaired Student’s
t-tests, one and two-way analysis of variance (ANOVA). The
treatment effect on Ki-67 and IHC markers was tested using an
analysis of covariance linear model with post-treatment score as
the response variable, adjusting for covariates (baseline Ki-67, age,
body mass index, tumour grade) and change in controls. Statistical
signiﬁcance was accepted at p < 0.05. In the ﬁgures, N/S, *, **, and
***, **** indicates not-signiﬁcant, p < 0.05, 0.01, 0.001, and 0.0001,
respectively.
RESULTS
Tumour hypoxia affects metformin response in vitro and in vivo
Pre- and post-intervention tumour biopsies were obtained in the
context of a pre-surgical window study of metformin in
women with endometrial cancer.8 Baseline tumour hypoxia was
assessed in pre-intervention biopsies (n= 40 women) and was
comparable in metformin-treated (n= 28) and control (n= 12)
patients. Tumour hypoxia, as measured by high expression of HIF-
1α (r= 0.42, p= 0.07) and CA-9 (r= 0.46, p= 0.03), was positively
correlated with tumour grade (atypical hyperplasia, n= 2, grade 1,
n= 15, grade 2, n= 1 and grade 3, n= 4) (Fig. 1a, b) and both
hypoxia markers positively correlated with each other (r= 0.45,
p= 0.004). We previously showed that short-term oral metformin
reduces cellular proliferation in some patients with endometrioid
endometrial cancer, as measured by a reduction in post-
intervention Ki-67 expression. The Ki-67 response was signiﬁcantly
lower in tumours with high HIF-1α expression [mean
adjusted difference −2.5% (95% CI −0.4, -4.6%) p= 0.018],
using an ANCOVA adjusting for baseline HIF-1α, baseline Ki-67,
BMI and tumour grade (Fig. 1c, d). There was also a trend
towards a lower Ki-67 response in tumours with high CA-9
(not statistically signiﬁcant). Low grade tumours showed the
greatest Ki-67 response to metformin, after adjusting for
hypoxia [mean adjusted difference −10.4% (95% CI 0.7, 20.1%)
p= 0.037].
In order to further demonstrate the role of hypoxia and
hyperglycaemia in metformin response, two endometrioid endo-
metrial cancer cell lines, Ishikawa and HEC1A cells were treated
with metformin in the presence of low (5.5 mM) or high (25 mM)
glucose concentrations in either normoxia (21% O2) or hypoxia
(1% O2). Metformin treatment for 72 hours in low glucose in
normoxia resulted in a dose-dependent inhibition of cell viability
in both cell lines (Fig. 2). The cytostatic effects of metformin were
less apparent in high glucose media and in hypoxia. This decrease
in response was more pronounced in Ishikawa cells, in both high
and low glucose (Fig. 2a, p < 0.05–0.001), while the protective
effects of hypoxia were only noted in low glucose in HEC1A cells
(Fig. 2b, p < 0.0001).
Short-term exposures to metformin (24 h) elicited no signiﬁcant
cytostatic effects, even in low (5.5 mM) glucose. However, when
exposing Ishikawa cells to ultra-low glucose concentrations
(0.5 and 1mM) for 24 h, a metformin dose-dependent cytostatic
effect was observed and these effects on cell viability were again
attenuated in hypoxia (Supplementary Fig. 3).
Metformin treatment reduces mitochondrial function with a
compensatory increase in mitochondrial biogenesis
We evaluated the effect of metformin on mitochondrial biogen-
esis and function in cells cultured in high and low glucose
concentrations. First, the impact of varying glucose concentrations
on mitochondrial biogenesis was assessed. Cells grown for 72 h in
low glucose had an increased mitochondrial mass compared with
cells grown in high glucose (Fig. 3a, p < 0.0001). There was no
change in overall mitochondrial function after normalising for
increased mitochondrial mass (Fig. 3c).
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Fig. 2 Hypoxia and high glucose reduce sensitivity of EC cells to metformin. a Ishikawa cells grown in low and high glucose were more
sensitive to the cytostatic effects of metformin in normoxia (n= 3 biological replicates). b HEC1A cells grown in low glucose were more
sensitive to the effects of metformin in normoxia. The bars represent the percentage cell viability ± SEM compared with untreated controls
(n= 3 biological replicates)
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Fig. 1 Tumour hypoxia as assessed by high expression of HIF-1α and CA-9 affects metformin response in vivo. Increased tumour hypoxia is
positively correlated with grade using a HIF-1α (r= 0.42, p= 0.07) and b CA-9 (r= 0.46, p= 0.03) IHC expression (n= 40 women). Numbers of
tumours in each grade are: 2 atypical hyperplasia (AEH), 15 grade 1, 19 grade 2 and 4 grade 3. Change in Ki-67 (i.e. response to metformin) was
correlated with baseline c HIF-1α and d CA-9. The ﬁgures illustrate the change in Ki-67 in endometrial tumour biopsies taken pre- and post-
metformin treatment in 28 patients. Response to metformin was lower in hypoxic tumours as assessed by HIF-1α [mean adjusted difference
2.5% (95% CI 0.4, 4.6%), p= 0.018] and approached statistical signiﬁcance with CA-9 [mean adjusted difference 10.9% (95% CI -2.0, 23.7%, p=
0.09) using an analysis of covariance
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Cells were then treated with metformin in high and low glucose
concentrations. Exposure to metformin resulted in an increase in
mitochondrial mass in the endometrial cancer cells relative to
untreated controls in both the high and low glucose-containing
media (Fig. 3d, p < 0.0001). However, after adjusting for this
increase in mitochondrial mass, there was a clear and signiﬁcant
decrease in mitochondrial function (as measured by a decrease in
mitochondrial membrane potential) in both cell lines at both
glucose concentrations (Fig. 3e, p < 0.01–0.0001). The decrease in
function was greatest under the low glucose conditions. In the
Ishikawa and HEC1A cells the metformin-induced reduction in
mitochondrial function compared to controls was 34 and 29% in
low glucose compared to reductions of 11 and 17% in high
glucose, respectively.
While it is difﬁcult to assess equivalent metformin-induced
changes in mitochondrial function in vivo, we were able to
evaluate mitochondrial mass. To do this we measured cytoplasmic
TOMM20 expression in the endometrial cancer biopsies taken at
recruitment to the pre-surgical window study compared with
tissue harvested at hysterectomy. TOMM20 was noted to
selectively stain the epithelial endometrial cancer cells and was
largely excluded from the adjacent tumour stromal compartment
(Fig. 4a), thus demonstrating a relative increase in mitochondria in
epithelial tumour compared with stromal cells. Additionally,
baseline TOMM20 expression showed a trend towards a positive
correlation with increasing tumour grade [Spearman’s correlation
r= 0.33 (95% CI −0.2, 0.63), p= 0.06]. The mean baseline scores of
metformin treated (n= 25) and control tumours (n= 8) were
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Fig. 3 Upper panel: Endometrial cancer cell lines have an increased mitochondrial mass in low glucose. a Ishikawa and HEC1A cells grown in
low glucose (grey bars) have increased mitochondrial mass compared with cells in high glucose (black bars). b Overall mitochondrial function
was decreased in cells grown in high glucose, compared with low glucose, however, c after adjusting for increased mitochondrial mass, there
was no change in mitochondrial function in Ishikawa and HEC1A cells. The bars represent the fold-change ± SEM compared with high glucose
(n= 3 biological replicates). Lower panel: Metformin reduces endometrial cancer cell mitochondrial function in both high and low glucose. EC
cells were treated in high (25mM, black bars) and low (5.5 mM, grey bars) glucose media with or without 2mM metformin for 72 h. The bars
represent fold-change ± SEM compared with untreated cells in cultured in high and low glucose. In Ishikawa and HEC1A cells, mitochondrial
mass was increased in both high and low glucose (a), while mitochondrial function was decreased (b) (n= 3 biological replicates)
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similar, 11.6 ± 2.8 and 11.0 ± 3, respectively (Fig. 4b). However,
TOMM20 expression increased by 2.1 (95% CI 0.2–4.0, p= 0.033) in
the hysterectomy samples taken post metformin treatment
compared with baseline. This was derived after adjusting for
baseline expression, age, BMI, tumour grade and change in the
control tumours. Thus, short-term metformin treatment is shown
to directly increase mitochondrial mass in women with endome-
trioid endometrial cancer.
Hypoxia and hyperglycaemia reduce the effect of metformin on
mitochondrial oxidative phosphorylation
We determined changes in mitochondrial function following
metformin treatment using the Seahorse metabolic analyser.
Experiments were carried out in normoxia (21% O2) and hypoxia
(3% O2) in the presence of high or low glucose concentrations. We
conﬁrmed that exposure of endometrial cancer cells to 3% O2 for
24 hours was sufﬁcient to increase the expression of hypoxia-
dependent genes (CA-9, VEGF and Glut-1) (Supplementary Fig. 4).
Ishikawa and HEC1A cells in media containing high or low
glucose were treated for 72 h in normoxia or hypoxia in the
presence or absence of 2 mM metformin. We observed similar
basal respirations rates in both glucose concentrations in Ishikawa
and HEC1A cell lines in normoxia. Treatment with metformin
impaired basal respiration of Ishikawa cells by 75 and 65% in low
and high glucose, respectively. In HEC1A cells, metformin caused
an almost 100% drop in respiration at both glucose concentra-
tions (Fig. 5a, b). In hypoxia (Fig. 5c, d), the cell lines showed
reduced mitochondrial basal respiration in both glucose concen-
trations. Treatment with metformin further impaired oxidative
phosphorylation for both cell lines. The changes in maximal
respiration in normoxia and hypoxia, at low and high glucose and
following treatment with and without metformin, generally
parallel those changes seen in basal respiration (5 E-H). The
accompanying data for effects on Proton leak and ATP production
are provided in Supplementary Fig. 5.
Ishikawa cells display increased glycolytic reserve in hypoxia with
concomitant reduction in metformin response
The signiﬁcant decrease in basal and maximal mitochondrial
respiration in untreated endometrial cancer cells in hypoxia (3%
O2) suggests a switch to glycolytic energy metabolism. Using
simultaneous extracellular acidiﬁcation rate (ECAR) measurements
taken during the mitochondrial stress test, we were able to
identify the glycolytic adaptations following oxygen, glucose and
metformin-mediated mitochondrial stress. Ishikawa cells in
particular, displayed increased ECAR and glycolytic reserve in
hypoxia in both glucose concentrations. In both cell lines
metformin has a substantial effect on reducing ECAR in normoxia
(p ≤ 0.01–0.0001), whereas under hypoxic conditions the effect,
although signiﬁcant, is much less (p ≤ 0.05–0.001) (Fig. 6a–d).
Finally, to ensure that the effects measured with the Seahorse
metabolic analyser can be related directly to the toxicity results in
Fig. 3, Supplementary Fig. 3, we carried out additional cell viability
experiments in normoxia versus hypoxia (3% O2) (Supplementary
Fig. 6). This conﬁrmed that in both low and high glucose, hypoxia
(3% O2) can attenuate the cytostatic effects of metformin (p <
0.05–0.0001).
DISCUSSION
In this study, we have shown that high glucose and hypoxia
reduce metformin response both in women with endometrioid
endometrial cancer and cancer cell line models. Endometrioid
endometrial or Type 1 cancers represent 80% of all endometrial
tumours and are thought to be driven by obesity and insulin
resistance,32 hence the potential for metformin to act on insulin-
dependent cancer signalling pathways.7 Metformin has shown
signiﬁcant promise as an anti-cancer treatment in various pre-
clinical studies25–27 and this has been recapitulated in single arm
clinical trials.8,10,13,14 The response to metformin, however, varied
between patient groups. Indeed, we found no overall effect of
metformin on Ki-67 expression in our own placebo-controlled trial
(PREMIUM), however, in an a priori subgroup analysis, BMI
modiﬁed metformin treatment effect, with non-obese women
showing greater Ki-67 response.9,33
While metformin’s anti-cancer activity is not fully understood,34
its role as a mitochondrial complex I inhibitor is established.35 The
dependence on mitochondrial respiratory activity is much
reduced under hypoxic conditions, hence tumour hypoxia could
inﬂuence response to metformin. High glucose concentrations are
recognised to modify the effect of metformin;28,36,37 in breast
cancer for example, mTOR inhibition by metformin was dimin-
ished in cells cultured in high glucose (11–25mM).38,39 A shift
towards glycolytic energy metabolism and reduced dependence
on oxidative phosphorylation has been proposed as a resistance
mechanism. In breast cancer cell lines, prolonged exposure to
metformin reduced mitochondrial OCR with compensatory
increased glycolysis.40
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Tumour hypoxia is recognised as a poor prognostic indicator in
endometrial cancer.41 In this study, HIF-1α and CA-9 expression on
endometrial cancer biopsies were used as surrogate markers of
hypoxia. Baseline HIF-1α and CA-9 were positively correlated to
tumour grade, a ﬁnding that corresponds with some publications
in endometrial cancer42,43 but not others.44,45 The baseline
expression of HIF-1α and CA-9 was comparable in the
metformin-treated and control patients. Assessing tumour hypoxia
in a hysterectomy specimen can be challenging as clamping the
uterine arteries and devascularising the uterus may itself
contribute to increased hypoxia. The baseline hypoxia expression,
however, is reliable as the live tumour is sampled and ﬁxed in
formalin immediately. Importantly, we have shown that Ki-67
response to metformin is signiﬁcantly lower in tumours with
higher baseline HIF-1α, suggesting decreased metformin response
in hypoxic tumours.
Our in vitro studies also conﬁrmed that endometrioid endo-
metrial cancer cells in hypoxia and those grown in low glucose in
normoxia are less responsive to the cytostatic effects of
metformin. This is consistent with previous observations where
metformin treatment showed a greater reduction in ovarian
xenograft tumour weight in normo-glycaemic mice, compared
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with hyper-glycaemic mice.46 In breast, endometrial and ovarian
cancer, low glucose conditions enhanced the cytostatic effects of
metformin on cancer cells,37,47 while hypoxia and HIF-1α
activation suppressed dichloroacetate (a glycolysis pathway
inhibitor) and metformin-induced cell death.48 While metformin
has been shown to affect apoptosis in cell culture models,49 our
clinical studies showed that metformin treatment was not
associated with an increase in apoptosis.8,9 Thus, we have used
cytostatic models for this study.
As metformin is thought to act on mitochondrial respiration, we
demonstrated that metformin treatment increases mitochondrial
biogenesis, while impairing mitochondrial function. These effects
were greater in low glucose using both ﬂow cytometry and
Seahorse mitochondrial stress tests. One interpretation is that high
glucose (hyperglycaemia) encourages cancer cells to harness
glycolytic pathways, thus protecting against a drug that targets
oxidative phosphorylation.50 There are a number of glucose-
regulated proteins in mitochondria51 that inﬂuence metabolism
and tumour growth,52 suggesting that metformin treatment may
cause signiﬁcant alterations in mitochondrial DNA level and
expression.
This is the ﬁrst study to demonstrate that metformin has a
direct effect on endometrioid endometrial tumour mitochondria
by increasing mitochondrial mass. This increase in mitochondrial
biogenesis may compensate for the effects on mitochondrial
function. Further, this study is the ﬁrst to report the validation and
use of the Seahorse analyser under hypoxic conditions. This has
allowed us to demonstrate that metformin-mediated effects on
mitochondrial function are reduced in high glucose and in
hypoxia, secondary to preferential glycolytic respiration. Our
in vitro ﬁndings of increased mitochondrial mass were mirrored
in endometrial tumour tissue from our pre-surgical study of
metformin. Tumours from patients on metformin treatment had a
signiﬁcant increase in post-treatment TOMM20 expression, an IHC
marker of mitochondrial mass. While it was not possible to directly
measure mitochondrial function in the tumour samples available,
it could be inferred that the increased mitochondrial mass
following clinical metformin treatment is accompanied by
reduced function. This mitochondrial dysfunction could contribute
to the inhibition of pro-proliferative pathways and the decrease in
cellular proliferation observed.
This study used translational models to explore potential
mechanisms of metformin response. A strength of the pre-
surgical study is the window design, which allowed the effects of
metformin to be tested directly in patients, thus bypassing animal
models. We were then able to conﬁrm our ﬁndings using
mechanistic cell line models. The pre-treatment endometrial
biopsies, however, were scanty and ﬁnite necessitating the use
of tissue micro-array. By the nature of the sampling device, the
biopsies were a scrape of the tumour surface and we were thus
unable to comment extensively on intra-tumoural heterogeneity
of the hypoxia markers. Similarly, further studies using speciﬁcally
collected endometrial cancer biopsies directly into a coating
buffer are required to accurately demonstrate the effects of
metformin on tumour mitochondrial function by measuring
cytochrome C oxidase staining. This detects the activity of
complex IV, reﬂecting the capacity of cells to undergo mitochon-
drial electron transport and oxidative phosphorylation.53
Hyperglycaemia and tumour hypoxia are likely to modify the
cytostatic/toxic effects of metformin. A dual approach to targeting
both glycolysis and oxidative phosphorylation is probably
necessary to achieve cancer cell death, particularly in glucose-
rich and hypoxic microenvironments. For example, the combina-
tion of short-term starvation and metformin, resulted in impaired
glycolytic ﬂux, inhibition of hexokinase II activity and impairment
of oxidative phosphorylation in colon cancer cell lines and murine
models.54 Alternatively, the addition of a glycolytic inhibitor, 2-
deoxyglucose may improve metformin response.55,56
We set out to establish metabolic determinants of metformin
response in endometrial cancer. Our data suggest that metformin
may have a therapeutic role for selected patients with normogly-
caemia and low grade, normoxic tumours. Hypoxic tumours were
less responsive to metformin treatment, while both hypoxia and
high glucose in growth media signiﬁcantly reduced the cytostatic
effect of metformin in vitro. An indiscriminate use of metformin in
all patients with endometrial cancer is likely to result in null
effects, as demonstrated by the heterogeneous response in our
patients. Thus, further studies may help characterise a subset of
patients most likely to derive long-term clinical beneﬁt.
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